促红细胞生成素治疗慢性心力衰竭合并贫血的临床研究

目的观察促红细胞生成素（EPO）治疗慢性心力衰竭合并贫血时的疗效及毒副作用。方法人选81例伴有贫血的慢性充血性心力衰竭（CHF）患者，随机分为治疗组（n=40例）和对照组（n=41例）；对照组给予心力衰竭的血管紧张素转换酶抑制剂、地高辛、利尿剂、B阻滞剂等药物口服治疗；治疗组给予心力衰竭的常规治疗的基础上同时给予皮下注射EPO，疗程1年。对两组临床结果以及不良反应进行比较分析。结果两组治疗前后比较LVEF、心功能分级、六分钟步行试验、Hb和BNP比较差异有统计学意义（P〈0．05）；两组治疗后观察指标比较差异有统计学意义（P〈0．05）；两组治疗副作用比较差异无统计学意义（P〉0．05）。结论EPO能改善慢性心力衰竭合并贫血患者心功能指标、提高运动耐量，无明显毒副作用。

Clinical research on erythropoietin in the treatment of chronic heart failure patients with anemia

Objective To observe the clinical effect and side effects of erythropoietin （EPO） for treating chronic heart failure （CHF） patients with anemia. Methods 81 patients with CHF and anemia were randomly divided into the treatment group （n=40） and the control group （n=41）; patients in the control group were given oral treatment of angiotensin converting enzyme inhibitors, digoxin, diuretics, β blocker. Patients in treatment group were given subcutaneous injection of EPO on the basis of the treatment for the control group. The clinical results and side effects of the two groups were comparatively analyzed. The course of treatment was 1 year. Results In the two groups, the LVEF, cardiac function, 6-rain-walking distance, hemoglobin and BNP after treatment were significantly improved, compared with those before treatment （P〈0.05）. The results of the treatment group were significantly better than those of the control group （P〈0.05） ; and the side effects had no obvious difference between the two groups （P〉0.05）. Conclusions EPO can improve the heart function indexes in patients with CHF and anemia, and can increase exercise tolerance, but without obvious side effects.